Table 2 Rates of neoadjuvant and adjuvant therapies in the total cohort of patients with clinically node-negative breast cancer and those with hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer

Total cohort

< 70 years

(n = 419)

≥ 70 years

(n = 163)

p-value

% missing data

 Neoadjuvant chemotherapy

34 (8.2%)

2 (1.2%)

0.003

1.0

 Neoadjuvant anti-hormonal therapy

15 (3.6%)

9 (5.5%)

0.429

1.0

 Adjuvant chemotherapy

74 (17.9%)

17 (10.8%)

0.051

1.7

 Adjuvant anti-hormonal therapy

307 (74.5%)

120 (75.0%)

0.99

1.7

 Adjuvant radiotherapy

280 (67.6%)

88 (55.0%)

0.006

1.4

HR + , Her2-

< 70 years

(n = 329)

≥ 70 years

(n = 136)

p-value

% missing data

 Neoadjuvant chemotherapy

7 (2.2%)

0 (0.0%)

0.191

5.1

 Neoadjuvant anti-hormonal therapy

14 (4.3%)

8 (5.9%)

0.629

5.1

 Adjuvant chemotherapy

44 (13.5%)

10 (7.6%)

0.111

5.9

 Adjuvant anti-hormonal therapy

262 (80.9%)

113 (84.3%)

0.458

5.7

 Adjuvant radiotherapy

222 (68.1%)

73 (54.5%)

0.008

5.3